Angiotensin II type 1/adenosine A 2A receptor oligomers: a novel target for tardive dyskinesia
Paulo A de Oliveira, James A R Dalton, Marc López-Cano, Adrià Ricarte, Xavier Morató, Filipe C Matheus, Andréia S Cunha, Christa E Müller, Reinaldo N Takahashi, Víctor Fernández-Dueñas, Jesús Giraldo, Rui D Prediger, Francisco Ciruela, Paulo A de Oliveira, James A R Dalton, Marc López-Cano, Adrià Ricarte, Xavier Morató, Filipe C Matheus, Andréia S Cunha, Christa E Müller, Reinaldo N Takahashi, Víctor Fernández-Dueñas, Jesús Giraldo, Rui D Prediger, Francisco Ciruela
Abstract
Tardive dyskinesia (TD) is a serious motor side effect that may appear after long-term treatment with neuroleptics and mostly mediated by dopamine D2 receptors (D2Rs). Striatal D2R functioning may be finely regulated by either adenosine A2A receptor (A2AR) or angiotensin receptor type 1 (AT1R) through putative receptor heteromers. Here, we examined whether A2AR and AT1R may oligomerize in the striatum to synergistically modulate dopaminergic transmission. First, by using bioluminescence resonance energy transfer, we demonstrated a physical AT1R-A2AR interaction in cultured cells. Interestingly, by protein-protein docking and molecular dynamics simulations, we described that a stable heterotetrameric interaction may exist between AT1R and A2AR bound to antagonists (i.e. losartan and istradefylline, respectively). Accordingly, we subsequently ascertained the existence of AT1R/A2AR heteromers in the striatum by proximity ligation in situ assay. Finally, we took advantage of a TD animal model, namely the reserpine-induced vacuous chewing movement (VCM), to evaluate a novel multimodal pharmacological TD treatment approach based on targeting the AT1R/A2AR complex. Thus, reserpinized mice were co-treated with sub-effective losartan and istradefylline doses, which prompted a synergistic reduction in VCM. Overall, our results demonstrated the existence of striatal AT1R/A2AR oligomers with potential usefulness for the therapeutic management of TD.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
References
- Brunner HR, Chang P, Wallach R, Sealey JE, Laragh JH. Angiotensin II vascular receptors: their avidity in relationship to sodium balance, the autonomic nervous system, and hypertension. J. Clin. Invest. 1972;51:58–67. doi: 10.1172/JCI106797.
- Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs. 1996;51:820–45. doi: 10.2165/00003495-199651050-00008.
- Hermann K, McDonald W, Unger T, Lang RE, Ganten D. Angiotensin biosynthesis and concentrations in brain of normotensive and hypertensive rats. J. Physiol. (Paris). 1984;79:471–80.
- Garrido-Gil P, Valenzuela R, Villar-Cheda B, Lanciego JL, Labandeira-Garcia JL. Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: an intracellular renin-angiotensin system in the nigra. Brain Struct. Funct. 2013;218:373–88. doi: 10.1007/s00429-012-0402-9.
- Saavedra JM. Brain Angiotensin II: New Developments, Unanswered Questions and Therapeutic Opportunities. Cell. Mol. Neurobiol. 2005;25:485–512. doi: 10.1007/s10571-005-4011-5.
- Saavedra JM. Angiotensin II AT(1) receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders. Cell. Mol. Neurobiol. 2012;32:667–81. doi: 10.1007/s10571-011-9754-6.
- Labandeira-GarcÃa JL, et al. Brain renin-angiotensin system and dopaminergic cell vulnerability. Front. Neuroanat. 2014;8:67. doi: 10.3389/fnana.2014.00067.
- Grammatopoulos TN, et al. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol. Neurodegener. 2007;2:1. doi: 10.1186/1750-1326-2-1.
- Zawada WM, et al. Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J. Neuroinflammation. 2011;8:129. doi: 10.1186/1742-2094-8-129.
- Sonsalla PK, et al. The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism. Exp. Neurol. 2013;250:376–83. doi: 10.1016/j.expneurol.2013.10.014.
- Agnati LF, Fuxe K, Zini I, Lenzi P, Hokfelt T. Aspects on receptor regulation and isoreceptor identification. Med. Biol. 1980;58:182–187.
- Fuxe K, et al. Evidence for the existence of receptor–receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides. J. neural Transm. 1983;18:165–179.
- Gomes I, et al. G Protein–Coupled Receptor Heteromers. Annu. Rev. Pharmacol. Toxicol. 2016;56:403–425. doi: 10.1146/annurev-pharmtox-011613-135952.
- Ciruela F, et al. Combining Mass Spectrometry and Pull-Down Techniques for the Study of Receptor Heteromerization. Direct Epitope–Epitope Electrostatic Interactions between Adenosine A 2A and Dopamine D 2 Receptors. Anal. Chem. 2004;76:5354–5363. doi: 10.1021/ac049295f.
- Ferre S, et al. An Update on Adenosine A2A-Dopamine D2 receptor interactions. Implications for the Function of G Protein-Coupled Receptors. Curr. Pharm. Des. 2008;14:1468–1474. doi: 10.2174/138161208784480108.
- Müller T. The safety of istradefylline for the treatment of Parkinson’s disease. Expert Opin. Drug Saf. 2015;14:769–75. doi: 10.1517/14740338.2015.1014798.
- Martínez-Pinilla E, et al. Dopamine D2 and angiotensin II type 1 receptors form functional heteromers in rat striatum. Biochem. Pharmacol. 2015;96:131–142. doi: 10.1016/j.bcp.2015.05.006.
- Pechlivanova DM, Georgiev VP. Interaction of angiotensin II and adenosine A1 and A2A receptor ligands on the writhing test in mice. Pharmacol. Biochem. Behav. 2002;72:23–8. doi: 10.1016/S0091-3057(01)00707-9.
- Tchekalarova J, Kambourova T, Georgiev V. Long-term theophylline treatment changes the effects of angiotensin II and adenosinergic agents on the seizure threshold. Brain Res. Bull. 2000;52:13–16. doi: 10.1016/S0361-9230(99)00254-3.
- Thakur S, Du J, Hourani S, Ledent C, Li JM. Inactivation of adenosine A2A receptor attenuates basal and angiotensin II-induced ROS production by Nox2 in endothelial cells. J. Biol. Chem. 2010;285:40104–40113. doi: 10.1074/jbc.M110.184606.
- Gomes CP, et al. Crosstalk between the signaling pathways triggered by angiotensin II and adenosine in the renal proximal tubules: Implications for modulation of Na+ -ATPase activity. Peptides. 2008;29:2033–2038. doi: 10.1016/j.peptides.2008.07.004.
- Lai EY, Patzak A. Persson, a. E. G. & Carlström, M. Angiotensin II enhances the afferent arteriolar response to adenosine through increases in cytosolic calcium. Acta Physiol. 2009;196:435–445. doi: 10.1111/j.1748-1716.2009.01956.x.
- Rongen Ga, Brooks SC, Ando SI, Abramson BL, Floras JS. Angiotensin AT1 receptor blockade abolishes the reflex sympatho- excitatory response to adenosine. J. Clin. Invest. 1998;101:769–776. doi: 10.1172/JCI480.
- Fernández-Dueñas V, et al. Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats. Dis. Model. Mech. 2015;8:57–63. doi: 10.1242/dmm.018143.
- Morris GM, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785–91. doi: 10.1002/jcc.21256.
- Zhang H, et al. Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor. J. Biol. Chem. 2015;290:29127–29139. doi: 10.1074/jbc.M115.689000.
- Ballesteros JA, Weinstein H. Integrated methods for the construction of three-dimensional models of structure–function relations in G protein-coupled receptors. Methods Neurosci. 1995;25:366–428. doi: 10.1016/S1043-9471(05)80049-7.
- Doré ASS, et al. Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine. Structure. 2011;19:1283–1293. doi: 10.1016/j.str.2011.06.014.
- Thévenin D, Lazarova T, Roberts MF, Robinson CR. Oligomerization of the fifth transmembrane domain from the adenosine A 2A receptor. Protein Sci. 2005;14:2177–2186. doi: 10.1110/ps.051409205.
- Canals M, et al. Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Neurochem. 2004;88:726–734. doi: 10.1046/j.1471-4159.2003.02200.x.
- Karip E, Turu G, Supeki K, Szidonya L, Hunyady L. Cross-inhibition of angiotensin AT1 receptors supports the concept of receptor oligomerization. Neurochem. Int. 2007;51:261–267. doi: 10.1016/j.neuint.2007.05.018.
- AbdAlla S, Lother H, Langer A, el Faramawy Y, Quitterer U. Factor XIIIA Transglutaminase Crosslinks AT1 Receptor Dimers of Monocytes at the Onset of Atherosclerosis. Cell. 2004;119:343–354. doi: 10.1016/j.cell.2004.10.006.
- Hansen JL, Theilade J, Haunso S, Sheikh SP. Oligomerization of Wild Type and Nonfunctional Mutant Angiotensin II Type I Receptors Inhibits G q Protein Signaling but Not ERK Activation. J. Biol. Chem. 2004;279:24108–24115. doi: 10.1074/jbc.M400092200.
- Fanelli F, Felline A. Dimerization and ligand binding affect the structure network of A2A adenosine receptor. Biochim. Biophys. Acta - Biomembr. 2011;1808:1256–1266. doi: 10.1016/j.bbamem.2010.08.006.
- Gracia E, et al. A2A adenosine receptor ligand binding and signalling is allosterically modulated by adenosine deaminase. Biochem. J. 2011;435:701–709. doi: 10.1042/BJ20101749.
- Liu W, et al. Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions. Science (80-.). 2012;337:232–236. doi: 10.1126/science.1219218.
- Lyskov S, et al. Serverification of Molecular Modeling Applications: The Rosetta Online Server That Includes Everyone (ROSIE) PLoS One. 2013;8:e63906. doi: 10.1371/journal.pone.0063906.
- Bonaventura J, et al. Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer. Proc. Natl. Acad. Sci. USA. 2015;112:E3609–18. doi: 10.1073/pnas.1507704112.
- Navarro G, et al. Quaternary structure of a G-protein-coupled receptor heterotetramer in complex with Gi and Gs. BMC Biol. 2016;14:26. doi: 10.1186/s12915-016-0247-4.
- Taura, J., Fernández-Dueñas, V. & Ciruela, F. Visualizing G Protein-Coupled Receptor-Receptor Interactions in Brain Using Proximity Ligation In Situ Assay. Curr. Protoc. Cell Biol. 67, 17.17.1–17.17.16 (2015).
- Ciruela F, et al. Adenosine receptor containing oligomers: their role in the control of dopamine and glutamate neurotransmission in the brain. Biochim. Biophys. Acta. 2011;1808:1245–1255. doi: 10.1016/j.bbamem.2011.02.007.
- Ferre S, et al. Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord. 2004;10:265–271. doi: 10.1016/j.parkreldis.2004.02.014.
- Ferre, S. et al. Adenosine A2A receptors and A2A receptor heteromers as key players in striatal function. Front. Neuroanat. 5 (2011).
- Parsons B, Togasaki DM, Kassir S, Przedborski S. Neuroleptics up-regulate adenosine A2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J. Neurochem. 1995;65:2057–64. doi: 10.1046/j.1471-4159.1995.65052057.x.
- Bishnoi M, Chopra K, Kulkarni SK. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur. J. Pharmacol. 2006;552:55–66. doi: 10.1016/j.ejphar.2006.09.010.
- Ivanova SA, et al. No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia. Hum. Psychopharmacol. Clin. Exp. 2012;27:334–337. doi: 10.1002/hup.2226.
- Andreassen OA, Jørgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog. Neurobiol. 2000;61:525–41. doi: 10.1016/S0301-0082(99)00064-7.
- Turrone P, Remington G, Nobrega JN. The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neurosci. Biobehav. Rev. 2002;26:361–80. doi: 10.1016/S0149-7634(02)00008-8.
- Fuxe K, et al. Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor field. Neuropsychopharmacology. 2014;39:131–55. doi: 10.1038/npp.2013.242.
- Fuxe K, Marcellino D, Genedani S, Agnati L. Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson’s disease. Mov. Disord. 2007;22:1990–2017. doi: 10.1002/mds.21440.
- Mendelsohn FA, Jenkins TA, Berkovic SF. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 1993;613:221–9. doi: 10.1016/0006-8993(93)90902-Y.
- Brown DC, Steward LJ, Ge J, Barnes NM. Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br. J. Pharmacol. 1996;118:414–20. doi: 10.1111/j.1476-5381.1996.tb15418.x.
- Villar-Cheda B, et al. Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: Implications for progression of Parkinson’s disease. Eur. J. Neurosci. 2010;32:1695–1706. doi: 10.1111/j.1460-9568.2010.07448.x.
- Villar-Cheda B, et al. Aging-related dysregulation of dopamine and angiotensin receptor interaction. Neurobiol. Aging. 2014;35:1726–1738. doi: 10.1016/j.neurobiolaging.2014.01.017.
- Borroto-Escuela DO, et al. Characterization of the A2AR-D2R interface: focus on the role of the C-terminal tail and the transmembrane helices. Biochem. Biophys. Res. Commun. 2010;402:801–807. doi: 10.1016/j.bbrc.2010.10.122.
- Moriyama K, Sitkovsky MV. Adenosine A2A Receptor Is Involved in Cell Surface Expression of A2B Receptor. J. Biol. Chem. 2010;285:39271–39288. doi: 10.1074/jbc.M109.098293.
- Ciruela F, et al. G protein-coupled receptor oligomerization for what? J. Recept. Signal Transduct. Res. 2010;30:322–330. doi: 10.3109/10799893.2010.508166.
- Ferré S, et al. Adenosine-cannabinoid receptor interactions. Implications for striatal function. Br. J. Pharmacol. 2010;160:443–53. doi: 10.1111/j.1476-5381.2010.00723.x.
- Yager LM, Garcia AF, Wunsch AM, Ferguson SM. The ins and outs of the striatum: Role in drug addiction. Neuroscience. 2015;301:529–541. doi: 10.1016/j.neuroscience.2015.06.033.
- Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease. Expert Opin. Investig. Drugs. 2005;14:729–738. doi: 10.1517/13543784.14.6.729.
- Jenner P, et al. Adenosine, adenosine A 2A antagonists, and Parkinson’s disease. Parkinsonism Relat. Disord. 2009;15:406–413. doi: 10.1016/j.parkreldis.2008.12.006.
- Muñoz A, Garrido-gil P, Dominguez-meijide A, Labandeira-garcia JL. Angiotensin type 1 receptor blockage reduces L -dopa-induced dyskinesia in the 6-OHDA model of Parkinson’ s disease. Involvement of vascular endothelial growth factor and interleukin-1 β. Exp. Neurol. 2014;261:720–732. doi: 10.1016/j.expneurol.2014.08.019.
- García-Negredo G, et al. Coassembly and coupling of SK2 channels and mGlu5 receptors. J. Neurosci. 2014;34:14793–802. doi: 10.1523/JNEUROSCI.2038-14.2014.
- Ledent C, et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature. 1997;388:674–8. doi: 10.1038/41771.
- Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. Special Report: The 1996 Guide for the Care and Use of Laboratory Animals. ILAR J. 1997;38:41–48. doi: 10.1093/ilar.38.1.41.
- Ciruela F, Fernández-Dueñas V. GPCR oligomerization analysis by means of BRET and dFRAP. Methods Mol. Biol. 2015;1272:133–144. doi: 10.1007/978-1-4939-2336-6_10.
- Garcia-Negredo G, et al. Coassembly and Coupling of SK2 Channels and mGlu5 Receptors. J. Neurosci. 2014;34:14793–14802. doi: 10.1523/JNEUROSCI.2038-14.2014.
- Matamales M, et al. Striatal medium-sized spiny neurons: identification by nuclear staining and study of neuronal subpopulations in BAC transgenic mice. PLoS One. 2009;4:e4770. doi: 10.1371/journal.pone.0004770.
- Sali A. Comparative protein modeling by satisfaction of spatial restraints. Mol. Med. Today. 1995;1:270–7. doi: 10.1016/S1357-4310(95)91170-7.
- Case DA, et al. The Amber biomolecular simulation programs. J. Comput. Chem. 2005;26:1668–1688. doi: 10.1002/jcc.20290.
- Pettersen EF, et al. UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25:1605–12. doi: 10.1002/jcc.20084.
- Kim S, et al. PubChem Substance and Compound databases. Nucleic Acids Res. 2016;44:D1202–D1213. doi: 10.1093/nar/gkv951.
- Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 2008;29:1859–65. doi: 10.1002/jcc.20945.
- Lomize MA, Lomize AL, Pogozheva ID, Mosberg HI. OPM: Orientations of Proteins in Membranes database. Bioinformatics. 2006;22:623–625. doi: 10.1093/bioinformatics/btk023.
- Huang J, MacKerell AD. CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data. J. Comput. Chem. 2013;34:2135–2145. doi: 10.1002/jcc.23354.
- Vanommeslaeghe K, et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 2010;31:671–90.
- Vanommeslaeghe K, Raman EP, MacKerell AD. Automation of the CHARMM General Force Field (CGenFF) II: Assignment of Bonded Parameters and Partial Atomic Charges. J. Chem. Inf. Model. 2012;52:3155–3168. doi: 10.1021/ci3003649.
- Vanommeslaeghe K, MacKerell AD. Automation of the CHARMM General Force Field (CGenFF) I: Bond Perception and Atom Typing. J. Chem. Inf. Model. 2012;52:3144–3154. doi: 10.1021/ci300363c.
- Harvey MJ, Giupponi G, Fabritiis G. De. ACEMD: Accelerating Biomolecular Dynamics in the Microsecond Time Scale. J. Chem. Theory Comput. 2009;5:1632–9. doi: 10.1021/ct9000685.
- Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33–8, 27–8 (1996).
- Cunha AS, et al. Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors. Behav. Brain Res. 2016;312:64–76. doi: 10.1016/j.bbr.2016.06.014.
Source: PubMed